2025 Q2 -tulosraportti
217 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·46 min sitten · MuokattuThe comparison between Circio Holding and the leading American players in circular RNA (circRNA) shows an enormous gap in valuation. While the largest American companies have raised billions of kroner, Circio is still valued as an early-stage company. Here is an overview of the most important players in the field as of March 2026: Valuation: Circio vs. Global Competitors Circio Holding Norway (Oslo) ~$15–20M (Market Cap) Preclinical. Focus on circRNA vectors and cancer vaccines. Orna Therapeutics USA (Boston) $500M+ (Privately funded) Collaboration with Merck worth up to $3.5 billion. Laronde USA (Boston) $440M+ (Series B) Part of Flagship Pioneering (same as Moderna). oRNAment USA (Boston) $100M+ (Series A) Focus on circular RNA for protein replacement. Why is the difference so big? Capital Access: American companies like Orna and Laronde are supported by gigantic venture funds (like Flagship and MPM Capital). This gives them billions to run parallel studies, while Circio must operate more frugally. Validation: Orna has already landed a massive deal with Merck. This set a "standard price" for circRNA technology that is many times higher than Circio's current market capitalization. Marketplace: Circio is listed on the Oslo Stock Exchange, which historically has lower multiples for biotechnology than Nasdaq in the USA. Circio's "Upside-Case" Analysts point out that if Circio succeeds with its in vivo Proof-of-Concept in Q2 2026, they will have validated the same technology that Orna and Laronde possess, but at a fraction of the price. Strategic goal: Circio's management has stated that their goal is to become an attractive acquisition candidate or partner for large pharmaceutical companies that want a foothold in circular RNA without paying "Boston prices". Summary: Circio is the "minnow" in a market characterized by giant investments. If they succeed with the technical milestones in 2026, the gap to American valuations can be significantly narrowed. REF.: GEMINI
·1 t sittenShould I buy now or wait?
1 t sitten1 t sittenI wish I could buy now, but unfortunately it's closed for Easter. 🐣
·4 t sitten"The Algorithm Slaughterhouse" – Why the brutal swings are tailor-made to steal your shares 🤖🩸 While we enjoy the green rally and Easter peace settles in, there's one thing that is vital to understand for those starting to feel the fear of heights: The massive swings we see along the way are not random. It's a deliberate shaking of the tree. Here's the brutal truth about how algorithms and big players use volatility to fleece nervous small investors before the real repricing starts: 1. Buying liquidity (Shaking the tree) 🌳 When a company takes off, big players need liquidity (shares) to build their positions. How do they get your shares when the trend is bright green and everyone wants to hold? They create brutal, temporary "dips". They slam the price down a few percent in seconds. Nervous small investors panic, think the top has been reached, and dump their shares to cut their losses. The machines thank and bow. 2. False sell walls (The Illusion) 🧱 Algorithms engage in psychological warfare. They place massive, false sell orders in the order book ("spoofing") to make it look like the rally is hitting a wall. The goal is for you to log in, be scared by the resistance, and secure small gains. The second you sell, the sell wall is pulled back, and the stock jumps further upwards. 3. The stop-loss hunt 🎯 This is the oldest trick in the book. The machines know that fearful people place "stop-loss" (automatic sale) orders right below the current price to secure their profit. By dumping a small block of shares on thin volume, they trigger an avalanche of these orders. They raid the stop-losses, pick up the shares at the bottom for a dirt-cheap price, and five minutes later we are back in the green. They literally steal from the fearful. Don't let a computer trick you into giving away your VC-ticket just because it swings a bit. Delete the stop-loss, lean back and let the machines starve while we climb further. Enjoy Easter. We know what we own. ☕️♟️
·8 t sittenGood morning and happy Easter. Brief summary: What in the world is mRNA and why is Circio's circVec so groundbreaking? many wonder. mRNA is used, for example, to get the body to recognize and attack cancer cells. mRNA is perhaps even best known as the platform in all COVID-19 vaccines, from e.g. Pfizer and Moderna. Problems with mRNA: Short lifespan (hours) Requires high dose, as the immune system intervenes Toxicity is high Variable effect Advantages of circVec platform: Much longer lifespan (up to 70x longer) Higher protein production (up to 50x) Lower dose = potentially lower toxicity (90% lower) Better target-specific effect Big Pharma previously told Erik (CEO) that they were very interested if they could deliver 3-5x higher protein production, but they showed 50x higher at 90% lower dose even. Secret Big Pharma giant has been testing their technology since November. How is it going, one might wonder? Based on Erik's (CEO) constant positivity both in Finansavisen, but also in the podcast from RADIUM, one can only assume that the study is a huge success. On April 13, the results will be published - these results will also be presented at the next ASGCT (May 11-15, Boston USA). They have been selected to give an oral abstract in front of everyone at the conference. Very few selected are allowed to do this. Press release first for attention. Presentation afterwards for validation. IF the feasibility study was a failure, they simply would not be selected for an oral abstract. ASGCT oral abstract looks like this (from 2025): (Skip to 47:20) https://www.asgct.org/education-career-resources/media-library/oral-abstract-session-innovations-in-in-vivo-targeting-of-hspcs-and-immune-cells The future for Circio looks incredibly bright. Such a Nextgen platform within gene therapy can almost not be priced. Either Circio will be sold to Big Pharma: Staggeringly high one-time payment (5, 8, 10 billion dollars??) Or the platform will be licensed out to Big Pharma over time for different categories. (higher profit, but over a longer period)
·3 t sittenWhat is the chance that Circio will be acquired?
·16 t sittenLove people's comments on my previous post hahaha. It was an April Fool's joke… The girls should of course also have a say. Hope you're enjoying the Easter beers and haven't sold, because this one I'm only selling when it's at 30-40.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
217 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·46 min sitten · MuokattuThe comparison between Circio Holding and the leading American players in circular RNA (circRNA) shows an enormous gap in valuation. While the largest American companies have raised billions of kroner, Circio is still valued as an early-stage company. Here is an overview of the most important players in the field as of March 2026: Valuation: Circio vs. Global Competitors Circio Holding Norway (Oslo) ~$15–20M (Market Cap) Preclinical. Focus on circRNA vectors and cancer vaccines. Orna Therapeutics USA (Boston) $500M+ (Privately funded) Collaboration with Merck worth up to $3.5 billion. Laronde USA (Boston) $440M+ (Series B) Part of Flagship Pioneering (same as Moderna). oRNAment USA (Boston) $100M+ (Series A) Focus on circular RNA for protein replacement. Why is the difference so big? Capital Access: American companies like Orna and Laronde are supported by gigantic venture funds (like Flagship and MPM Capital). This gives them billions to run parallel studies, while Circio must operate more frugally. Validation: Orna has already landed a massive deal with Merck. This set a "standard price" for circRNA technology that is many times higher than Circio's current market capitalization. Marketplace: Circio is listed on the Oslo Stock Exchange, which historically has lower multiples for biotechnology than Nasdaq in the USA. Circio's "Upside-Case" Analysts point out that if Circio succeeds with its in vivo Proof-of-Concept in Q2 2026, they will have validated the same technology that Orna and Laronde possess, but at a fraction of the price. Strategic goal: Circio's management has stated that their goal is to become an attractive acquisition candidate or partner for large pharmaceutical companies that want a foothold in circular RNA without paying "Boston prices". Summary: Circio is the "minnow" in a market characterized by giant investments. If they succeed with the technical milestones in 2026, the gap to American valuations can be significantly narrowed. REF.: GEMINI
- ·1 t sittenShould I buy now or wait?1 t sitten1 t sittenI wish I could buy now, but unfortunately it's closed for Easter. 🐣
- ·4 t sitten"The Algorithm Slaughterhouse" – Why the brutal swings are tailor-made to steal your shares 🤖🩸 While we enjoy the green rally and Easter peace settles in, there's one thing that is vital to understand for those starting to feel the fear of heights: The massive swings we see along the way are not random. It's a deliberate shaking of the tree. Here's the brutal truth about how algorithms and big players use volatility to fleece nervous small investors before the real repricing starts: 1. Buying liquidity (Shaking the tree) 🌳 When a company takes off, big players need liquidity (shares) to build their positions. How do they get your shares when the trend is bright green and everyone wants to hold? They create brutal, temporary "dips". They slam the price down a few percent in seconds. Nervous small investors panic, think the top has been reached, and dump their shares to cut their losses. The machines thank and bow. 2. False sell walls (The Illusion) 🧱 Algorithms engage in psychological warfare. They place massive, false sell orders in the order book ("spoofing") to make it look like the rally is hitting a wall. The goal is for you to log in, be scared by the resistance, and secure small gains. The second you sell, the sell wall is pulled back, and the stock jumps further upwards. 3. The stop-loss hunt 🎯 This is the oldest trick in the book. The machines know that fearful people place "stop-loss" (automatic sale) orders right below the current price to secure their profit. By dumping a small block of shares on thin volume, they trigger an avalanche of these orders. They raid the stop-losses, pick up the shares at the bottom for a dirt-cheap price, and five minutes later we are back in the green. They literally steal from the fearful. Don't let a computer trick you into giving away your VC-ticket just because it swings a bit. Delete the stop-loss, lean back and let the machines starve while we climb further. Enjoy Easter. We know what we own. ☕️♟️
- ·8 t sittenGood morning and happy Easter. Brief summary: What in the world is mRNA and why is Circio's circVec so groundbreaking? many wonder. mRNA is used, for example, to get the body to recognize and attack cancer cells. mRNA is perhaps even best known as the platform in all COVID-19 vaccines, from e.g. Pfizer and Moderna. Problems with mRNA: Short lifespan (hours) Requires high dose, as the immune system intervenes Toxicity is high Variable effect Advantages of circVec platform: Much longer lifespan (up to 70x longer) Higher protein production (up to 50x) Lower dose = potentially lower toxicity (90% lower) Better target-specific effect Big Pharma previously told Erik (CEO) that they were very interested if they could deliver 3-5x higher protein production, but they showed 50x higher at 90% lower dose even. Secret Big Pharma giant has been testing their technology since November. How is it going, one might wonder? Based on Erik's (CEO) constant positivity both in Finansavisen, but also in the podcast from RADIUM, one can only assume that the study is a huge success. On April 13, the results will be published - these results will also be presented at the next ASGCT (May 11-15, Boston USA). They have been selected to give an oral abstract in front of everyone at the conference. Very few selected are allowed to do this. Press release first for attention. Presentation afterwards for validation. IF the feasibility study was a failure, they simply would not be selected for an oral abstract. ASGCT oral abstract looks like this (from 2025): (Skip to 47:20) https://www.asgct.org/education-career-resources/media-library/oral-abstract-session-innovations-in-in-vivo-targeting-of-hspcs-and-immune-cells The future for Circio looks incredibly bright. Such a Nextgen platform within gene therapy can almost not be priced. Either Circio will be sold to Big Pharma: Staggeringly high one-time payment (5, 8, 10 billion dollars??) Or the platform will be licensed out to Big Pharma over time for different categories. (higher profit, but over a longer period)·3 t sittenWhat is the chance that Circio will be acquired?
- ·16 t sittenLove people's comments on my previous post hahaha. It was an April Fool's joke… The girls should of course also have a say. Hope you're enjoying the Easter beers and haven't sold, because this one I'm only selling when it's at 30-40.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
217 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·46 min sitten · MuokattuThe comparison between Circio Holding and the leading American players in circular RNA (circRNA) shows an enormous gap in valuation. While the largest American companies have raised billions of kroner, Circio is still valued as an early-stage company. Here is an overview of the most important players in the field as of March 2026: Valuation: Circio vs. Global Competitors Circio Holding Norway (Oslo) ~$15–20M (Market Cap) Preclinical. Focus on circRNA vectors and cancer vaccines. Orna Therapeutics USA (Boston) $500M+ (Privately funded) Collaboration with Merck worth up to $3.5 billion. Laronde USA (Boston) $440M+ (Series B) Part of Flagship Pioneering (same as Moderna). oRNAment USA (Boston) $100M+ (Series A) Focus on circular RNA for protein replacement. Why is the difference so big? Capital Access: American companies like Orna and Laronde are supported by gigantic venture funds (like Flagship and MPM Capital). This gives them billions to run parallel studies, while Circio must operate more frugally. Validation: Orna has already landed a massive deal with Merck. This set a "standard price" for circRNA technology that is many times higher than Circio's current market capitalization. Marketplace: Circio is listed on the Oslo Stock Exchange, which historically has lower multiples for biotechnology than Nasdaq in the USA. Circio's "Upside-Case" Analysts point out that if Circio succeeds with its in vivo Proof-of-Concept in Q2 2026, they will have validated the same technology that Orna and Laronde possess, but at a fraction of the price. Strategic goal: Circio's management has stated that their goal is to become an attractive acquisition candidate or partner for large pharmaceutical companies that want a foothold in circular RNA without paying "Boston prices". Summary: Circio is the "minnow" in a market characterized by giant investments. If they succeed with the technical milestones in 2026, the gap to American valuations can be significantly narrowed. REF.: GEMINI
- ·1 t sittenShould I buy now or wait?1 t sitten1 t sittenI wish I could buy now, but unfortunately it's closed for Easter. 🐣
- ·4 t sitten"The Algorithm Slaughterhouse" – Why the brutal swings are tailor-made to steal your shares 🤖🩸 While we enjoy the green rally and Easter peace settles in, there's one thing that is vital to understand for those starting to feel the fear of heights: The massive swings we see along the way are not random. It's a deliberate shaking of the tree. Here's the brutal truth about how algorithms and big players use volatility to fleece nervous small investors before the real repricing starts: 1. Buying liquidity (Shaking the tree) 🌳 When a company takes off, big players need liquidity (shares) to build their positions. How do they get your shares when the trend is bright green and everyone wants to hold? They create brutal, temporary "dips". They slam the price down a few percent in seconds. Nervous small investors panic, think the top has been reached, and dump their shares to cut their losses. The machines thank and bow. 2. False sell walls (The Illusion) 🧱 Algorithms engage in psychological warfare. They place massive, false sell orders in the order book ("spoofing") to make it look like the rally is hitting a wall. The goal is for you to log in, be scared by the resistance, and secure small gains. The second you sell, the sell wall is pulled back, and the stock jumps further upwards. 3. The stop-loss hunt 🎯 This is the oldest trick in the book. The machines know that fearful people place "stop-loss" (automatic sale) orders right below the current price to secure their profit. By dumping a small block of shares on thin volume, they trigger an avalanche of these orders. They raid the stop-losses, pick up the shares at the bottom for a dirt-cheap price, and five minutes later we are back in the green. They literally steal from the fearful. Don't let a computer trick you into giving away your VC-ticket just because it swings a bit. Delete the stop-loss, lean back and let the machines starve while we climb further. Enjoy Easter. We know what we own. ☕️♟️
- ·8 t sittenGood morning and happy Easter. Brief summary: What in the world is mRNA and why is Circio's circVec so groundbreaking? many wonder. mRNA is used, for example, to get the body to recognize and attack cancer cells. mRNA is perhaps even best known as the platform in all COVID-19 vaccines, from e.g. Pfizer and Moderna. Problems with mRNA: Short lifespan (hours) Requires high dose, as the immune system intervenes Toxicity is high Variable effect Advantages of circVec platform: Much longer lifespan (up to 70x longer) Higher protein production (up to 50x) Lower dose = potentially lower toxicity (90% lower) Better target-specific effect Big Pharma previously told Erik (CEO) that they were very interested if they could deliver 3-5x higher protein production, but they showed 50x higher at 90% lower dose even. Secret Big Pharma giant has been testing their technology since November. How is it going, one might wonder? Based on Erik's (CEO) constant positivity both in Finansavisen, but also in the podcast from RADIUM, one can only assume that the study is a huge success. On April 13, the results will be published - these results will also be presented at the next ASGCT (May 11-15, Boston USA). They have been selected to give an oral abstract in front of everyone at the conference. Very few selected are allowed to do this. Press release first for attention. Presentation afterwards for validation. IF the feasibility study was a failure, they simply would not be selected for an oral abstract. ASGCT oral abstract looks like this (from 2025): (Skip to 47:20) https://www.asgct.org/education-career-resources/media-library/oral-abstract-session-innovations-in-in-vivo-targeting-of-hspcs-and-immune-cells The future for Circio looks incredibly bright. Such a Nextgen platform within gene therapy can almost not be priced. Either Circio will be sold to Big Pharma: Staggeringly high one-time payment (5, 8, 10 billion dollars??) Or the platform will be licensed out to Big Pharma over time for different categories. (higher profit, but over a longer period)·3 t sittenWhat is the chance that Circio will be acquired?
- ·16 t sittenLove people's comments on my previous post hahaha. It was an April Fool's joke… The girls should of course also have a say. Hope you're enjoying the Easter beers and haven't sold, because this one I'm only selling when it's at 30-40.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt